Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viamet Pharmaceuticals has started patient dosing in a single-ascending dose Phase 1 trial evaluating antifungal agent VT-1161.
Subscribe to our email newsletter
Currently under development by Viamet Pharma,VT-1161 is intended for the treatment of fungal infections in humans.
Viamet president and CEO Robert Schotzinger said in preclinical studies, VT-1161 has been shown to be one of the potent antifungal agents ever discovered against a wide range of pathogenic fungi which cause diseases such as invasive candidiasis and onychomycosis.
"However, despite its high potency, VT-1161 has also exhibited a very impressive safety and pharmacokinetic profile," Schotzinger said.